Clinical Rationale for a Routine Testing Schedule Using Donor-Derived Cell-Free DNA After Kidney Transplantation

Akshta Pai; Joshua T. Swan; David Wojciechowski; Yasir Qazi; Sham Dholakia; Grigoriy Shekhtman; Anas Abou-Ismail; Dhiren Kumar

doi:10.12659/AOT.932249

02 July 2021 : Review article

Clinical Rationale for a Routine Testing Schedule Using Donor-Derived Cell-Free DNA After Kidney Transplantation

Akshta Pai^1ADEF*, Joshua T. Swan

^23ADEF, David Wojciechowski^4ADEF, Yasir Qazi^5ADEF, Sham Dholakia^6ADEF, Grigoriy Shekhtman^6ADEF, Anas Abou-Ismail^6ADEF, Dhiren Kumar

^7ADEF

DOI: 10.12659/AOT.932249

Ann Transplant 2021; 26:e932249

Authors information Article notes Copyright and License information

Background Immunosuppression in the First Year After Transplantation Rationale of dd-cfDNA Surveillance Time Points Quarterly Surveillance: Year 2 and Beyond Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 1 Graphic depicting the potential added value of donor-derived cell-free DNA (dd-cfDNA) surveillance for augmenting clinical decision making in posttransplant management. SCr – serum creatinine; DSA – donor-specific antibodies; PRA – panel reactive antibodies; IS – immunosuppressive therapy.

Back to the Article

Clinical Rationale for a Routine Testing Schedule Using Donor-Derived Cell-Free DNA After Kidney Transplantation

Your Privacy